Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs - Wikidata - wikimedia - TriplyDB

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

http://www.wikidata.org/entity/Q28487121

about

Thioridazine induces major changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus aureus USA300 Thioridazine: resurrection as an antimicrobial agent?Characterization of the Mycobacterium tuberculosis 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase: potential for drug development Novel adjunctive therapies for the treatment of tuberculosis Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation Type-II NADH:quinone oxidoreductase from Staphylococcus aureus has two distinct binding sites and is rate limited by quinone reduction Functional characterization and target validation of alternative complex I of Plasmodium falciparum mitochondria Mycobacterium tuberculosis nuoG is a virulence gene that inhibits apoptosis of infected host cells A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis Partial Saturation of Menaquinone in Mycobacterium tuberculosis: Function and Essentiality of a Novel Reductase, MenJ Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis Mycobacterium tuberculosis type II NADH-menaquinone oxidoreductase catalyzes electron transfer through a two-site ping-pong mechanism and has two quinone-binding sites Annotated compound data for modulators of detergent-solubilised or lipid-reconstituted respiratory type II NADH dehydrogenase activity obtained by compound library screening.Identification of gene targets against dormant phase Mycobacterium tuberculosis infections Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis.High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis Characterization of the type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the bactericidal action of phenothiazines Aspergillus fumigatus metabolism: clues to mechanisms of in vivo fungal growth and virulence Function of the cytochrome bc1-aa3 branch of the respiratory network in mycobacteria and network adaptation occurring in response to its disruption.Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.The mycobacterial cell envelope-lipids Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria.The challenge of new drug discovery for tuberculosis.Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.The tuberculosis drug discovery and development pipeline and emerging drug targets.The cytochrome bd-type quinol oxidase is important for survival of Mycobacterium smegmatis under peroxide and antibiotic-induced stress.Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence Antitubercular pharmacodynamics of phenothiazines Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps.Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis.The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis Physiology of mycobacteria The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target.New drugs and vaccines for drug-resistant Mycobacterium tuberculosis infections.Perturbation of cytochrome c maturation reveals adaptability of the respiratory chain in Mycobacterium tuberculosis.

P2860

Q21133515-D443C0C7-4BA9-44B4-82D6-EFC7B71D1AF8 Q24650111-7704930D-819C-42B4-89F4-431C7414CA31 Q24681801-1F8F0FAA-5CF8-4D1C-94A1-7C3445FD48A9 Q26829957-E4E5DEDF-3E8C-4C32-A287-748CD0F37044 Q27688947-BE332629-9B80-4DCD-A074-F819AB22A862 Q27701552-4F2D41F9-E067-4C45-9742-33BF836E321E Q27973427-F6203E6A-8B4E-47B9-803E-3BFB931C88F2 Q28469257-003BA3FF-602D-4B4E-A24B-E3E0548776C1 Q28473609-6A1D3A41-39A3-451F-9F7C-5712D5B03D4E Q28482080-0D0B8D10-9BBF-418B-A4E1-FE1BBC7CF07C Q28487581-4684D98D-624F-4D4F-9AF0-6CD301C6BD90 Q28550401-F649E5E3-DDE8-4F53-A05B-09BB24A4CF2F Q28660144-243692D5-7616-4FA7-8A9C-E7E08F0F3F77 Q31044036-A2D87C56-F917-4713-885F-9D49ACD6FFD7 Q33291875-A419B4A5-C1EA-4CB5-B201-9AC7709E1FDB Q33476065-8AF1C5C8-07CC-4CA7-9D60-A6AD8A5D6080 Q33503956-2B018092-EFE8-46F5-B1AE-F23B4FCE8CE5 Q33607162-F6B7F76D-7895-4898-BA20-EB0E5523A206 Q33717526-8D6EB92F-1893-49E8-8BE1-B3C8E0DFD3F7 Q33999784-E584FEAD-E1C7-40F5-AEDA-366635E27713 Q34048408-B09A6AEA-1E3D-43E5-83FE-63FED199A577 Q34081424-2B0D7E3E-0291-412A-BEC4-D7DC46D04228 Q34123800-EAC8488B-A846-4810-BB13-D27780AE7D3B Q34355375-85A02B0C-F13E-47B2-BEF5-36F8B425F94B Q34383371-D9554328-D6C9-43DB-92A5-5A96E19A007F Q34660424-FFA08849-DA21-4F9D-AAB5-CBDD650BD9A8 Q34695666-090C41EE-185F-4383-AD5B-AD262F7F34B1 Q35664209-2FCC6606-CABC-45BC-97BE-7FC6A739AFE0 Q35670401-3E78CEFB-DECD-4678-BB1A-88768A6A9D72 Q36032548-06ADB9CF-9BB9-4594-BB13-F1FA5A1AF299 Q36393640-A7765A6F-9B84-4E70-BB59-134E0D6210E0 Q36561241-99ED4B3C-2E49-4690-B939-849DD466178E Q36675149-49DCDA79-A4A3-4273-91C7-15F1D7A2E9AE Q36705837-E7B7FCA8-B470-4EE6-924D-81B775E8BA0D Q36782015-12B245E2-042E-479B-B55C-C6AD9EC113EB Q36954404-7684C5B4-D529-4B7D-920F-87C246EF145A Q37058451-097D3E05-7D26-4D1D-BEF1-91735524F218 Q37107614-9E1592DE-2500-4287-801A-F0CD8ECD75AB Q37150326-050C78C9-4115-4A0D-97A9-A95F6C9B595B Q37194302-7FE66A7C-DF23-41CE-8D20-FE80C967D977

P2860

Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs

http://www.wikidata.org/entity/Q28487121

description

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

article publié dans les Procee ...... f the United States of America

@fr

artículu científicu espublizáu en 2005

@ast

im März 2005 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2005/03/22)

@sk

vědecký článek publikovaný v roce 2005

@cs

wetenschappelijk artikel (gepubliceerd op 2005/03/22)

@nl

наукова стаття, опублікована в березні 2005

@uk

name

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@ast

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@en

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@nl

type

label

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@ast

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@en

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@nl

prefLabel

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@ast

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@en

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@nl

P1433

Q28487121-FBFEE802-502C-4AEE-8CC6-633337F82679

P1476

Q28487121-94AD5DDC-17E7-4E12-B404-6A9AD1F9BB9A

P2093

Q28487121-1359A66A-CEDD-47BB-BE7F-8D9D5C38F4D1

Q28487121-2668B31A-2708-4A79-8A48-A42C22F50246

Q28487121-3BB05022-977B-4061-9712-494B99781073

Q28487121-5C9E207C-77B8-4EB9-93FC-0D4384AFF70C

Q28487121-6654272D-71CD-449E-BA11-DA659E0EF25E

Q28487121-6C9ACC5F-75FF-48D6-8505-9CBE1A9DDA04

Q28487121-9B5D6C0A-98EB-4C0F-A254-9D330A34166D

Q28487121-C396AEA5-3DA0-42E8-B99A-AD4AF2B3C4EE

Q28487121-F1A4658B-B944-4DBD-9D36-48BA700F273A

Q28487121-F1D5D5FA-20E5-48A1-B1AC-113592978015

P2860

Q28487121-07CE76E2-8D8C-4332-8514-A0C3765924A8

Q28487121-0ACA3FD3-1CA3-4265-937C-B5FCCA02E3C2

Q28487121-0D2D4DBF-BC99-42F9-AB46-000EAD1BB445

Q28487121-10058A74-A7F0-4FF7-AE61-14D4E8DC0566

Q28487121-17ABB6C6-955A-4D68-A2B0-2F538DE4370C

Q28487121-19833B86-F4BD-4977-B6E4-28C15EF77925

Q28487121-1FEA29C7-96BF-4DBF-9C6E-AC86AD69F107

Q28487121-244B81C1-CE4E-45FE-B5D4-4916EBBEC4ED

Q28487121-24790B7A-5FCB-4E14-9F62-B12154BC69A4

Q28487121-3740ECAD-8A9B-481C-8FA8-47ECACF89A65

P304

Q28487121-62F67395-DB17-4DD7-8673-409F185717E0

P31

Q28487121-BA4764FA-536B-4A4A-AE0C-622B37EDDE51

P3181

Q28487121-61131289-97A0-4AB7-B83C-63ECAE93F26C

P356

Q28487121-9E5F9200-1A43-4856-B626-2EF51FD731F3

P407

Q28487121-88F51118-AE4F-4FF5-AB9D-814A8CAA3D74

P433

Q28487121-F9F2E937-5708-4901-8CC3-F223E8DA4EBC

P478

Q28487121-548143F5-02BB-4DA2-9622-8E572C77882B

P577

Q28487121-EFC8388B-1C75-4EB1-B6EE-BC0977B809E4

P5875

Q28487121-860F9B41-7407-4C61-9FED-91FF1ED67C9E

P698

Q28487121-137CC84C-C055-4C09-ABFB-57B472F859E5

P932

Q28487121-31B89A71-C937-411E-9F77-6A503798A5B1

P3181

P356

PNAS.0500469102

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Inhibitors of type II NADH:men ...... class of antitubercular drugs

@en

P2093

Andrew A. McColm

http://www.w3.org/2001/XMLSchema#string

Andrew Avarbock

http://www.w3.org/2001/XMLSchema#string

David Avarbock

http://www.w3.org/2001/XMLSchema#string

Douglas Helm

http://www.w3.org/2001/XMLSchema#string

Edward A. Weinstein

http://www.w3.org/2001/XMLSchema#string

Harvey Rubin

http://www.w3.org/2001/XMLSchema#string

John T. Lonsdale

http://www.w3.org/2001/XMLSchema#string

Ken Duncan

http://www.w3.org/2001/XMLSchema#string

Lin-Sheng Li

http://www.w3.org/2001/XMLSchema#string

Takahiro Yano

http://www.w3.org/2001/XMLSchema#string

P2860

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

Genes required for mycobacterial growth defined by high density mutagenesis

Studies on antituberculotic action of some phenothiazine derivatives in vitro

Antitubercular activity of trifluoperazine, a calmodulin antagonist

Chlorpromazine: a drug potentially useful for treating mycobacterial infections

NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis

Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis

Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling

Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program

P304

4548–4553

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2621503

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0500469102

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7966387

http://www.w3.org/2001/XMLSchema#string

P698

15767566

http://www.w3.org/2001/XMLSchema#string

P932

555520

http://www.w3.org/2001/XMLSchema#string